NEW YORK (GenomeWeb News) - BioServe said today that it has inked a partnership with Seegene to develop a detection system to diagnose a number of infectious diseases in India, BioServe said today.
Seegene, which is based in Seoul and maintains a US headquarters in Rockville, Md., will access BioServe's repository of Indian DNA samples to collaborate on development of a test for several sexually transmitted diseases, tuberculosis, and HIV-1 and HIV-2, BioServe said.
BioServe, which retains research and production facilities in Hyberabad, India, will use Seegene's Seeplex STD detection system to test for Mycoplasma hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae, Chlamydia trachomatis, herpes simplex virus 2, and human papillomavirus. The assay also will test for tuberculosis, which BioServe said.
BioServe cited a World Health Organization estimate that India sees roughly 1.8 million new cases of TB each year. BioServe also said there are more than 5.1 million Indians currently infected with HIV.
The test is based on Seegene's dual priming oligonucleotide technology, which is a DNA amplification method that can be used in simultaneous multi-pathogen detection assays, BioServe said.
Specific financial terms of the agreement were not released.
Jessica Joung, manager of Seegene's Rockville branch, told GenomeWeb Daily News today that the two companies plan to evaluate the collaboration at the end of 2007, and decide at that time whether to extend the agreement.